Illumina, Inc. $ILMN Shares Sold by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 8.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 43,677 shares of the life sciences company’s stock after selling 4,272 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Illumina were worth $5,748,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of ILMN. Elyxium Wealth LLC acquired a new position in shares of Illumina during the fourth quarter valued at $25,000. Board of the Pension Protection Fund acquired a new position in shares of Illumina during the fourth quarter valued at $26,000. Creative Capital Management Investments LLC increased its holdings in shares of Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares during the period. TD Waterhouse Canada Inc. acquired a new position in shares of Illumina during the fourth quarter valued at $26,000. Finally, Laurel Wealth Advisors LLC acquired a new position in shares of Illumina during the fourth quarter valued at $26,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Price Performance

NASDAQ:ILMN opened at $144.41 on Friday. The business’s 50-day moving average price is $130.45 and its 200 day moving average price is $130.91. The firm has a market cap of $21.85 billion, a P/E ratio of 26.26, a PEG ratio of 2.40 and a beta of 1.42. Illumina, Inc. has a 52-week low of $78.55 and a 52-week high of $155.53. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.Illumina’s revenue was up 4.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, sell-side analysts predict that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

Insider Transactions at Illumina

In related news, Director Keith A. Meister sold 225,067 shares of the stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $145.55, for a total value of $32,758,501.85. Following the completion of the transaction, the director owned 3,604,441 shares in the company, valued at $524,626,387.55. This trade represents a 5.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the completion of the transaction, the senior vice president owned 15,056 shares of the company’s stock, valued at $2,093,386.24. This trade represents a 4.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 330,160 shares of company stock worth $48,028,308. 2.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Weiss Ratings lowered Illumina from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Piper Sandler lowered their target price on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a report on Monday, February 9th. Wall Street Zen lowered Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Robert W. Baird set a $137.00 target price on Illumina in a report on Friday, February 6th. Finally, Evercore reaffirmed an “outperform” rating on shares of Illumina in a report on Friday, May 1st. Seven analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Illumina has an average rating of “Hold” and a consensus target price of $137.75.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.